Sarah Hersey

At Bristol Myers Squibb, Sarah is responsible for leading a research and development team of more than 100 scientists supporting translational sciences and diagnostics. She leads a team at Bristol Myers Squibb that supported more than 20 drug approvals, top-line results, and other key regulatory milestones in a single year during the pandemic. Prior to her time with Bristol Myers Squibb, Sarah was Head of Precision Medicine and Vice President at Celgene, which was acquired by Bristol Myers Squibb in 2019.